Abnormal cell proliferation is a major hallmark of cancer. Several proteins are involved in the cell cycle, and most of these regulate the positive or negative control of cyclin-dependent kinases.

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be ...

A new metabolic mechanism describes how tumors disable “gatekeeper” cells to prevent immune response to cancer.

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the ...

Stem cells are the body's ultimate shape-shifters, sustaining tissues by balancing two competing demands: maintaining their ...

T cells dynamically adapt to signals in the TME, transitioning between effector, exhausted, and regulatory states. Cellular interactions, metabolic stress, and physical barriers (e.g., ECM) shape ...

There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses. However, these resistance mechanisms are not yet fully ...

The tumor microenvironment (TME) is one of the most formidable obstacles in the fight against cancer. While therapies that target cancer cells have been revolutionary, many patients still do not ...

Treatment with programmed cell death 1/programmed cell death ligand 1 inhibitors for Kaposi sarcoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American ...